相关实验视频

Updated: May 5, 2026

Controlled Cortical Impact Model for Traumatic Brain Injury

Controlled Cortical Impact Model for Traumatic Brain Injury

Published on: August 5, 2014

塞沃弗兰通过BLACAT1/miR-361-3p轴触发质细胞损伤,导致认知障碍

Jipeng Wen¹, Feiyu Long², Xiaoying Wang¹

¹Department of Anesthesiology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.

Synapse (New York, N.Y.)

|March 3, 2026

概括

暴露于塞沃氨酸 (Sev) 会增加BLACAT1,损害神经元和损害记忆. 通过miR-361-3p准BLACAT1可能会防止Sev诱导的认知功能障碍.

科学领域:

神经科学是一个神经科学.
分子生物学分子生物学
细胞生物学细胞生物学

背景情况:

塞沃弗兰 (Sev) 是一种麻醉剂.
神经细胞损伤是麻醉期间的一个担忧.
由于Sev引起的神经元损伤的调节机制需要进一步阐明.

研究的目的:

为了研究BLACAT1在sevoflurane诱导的神经元细胞损伤中的作用.
在这种情况下,探索涉及BLACAT1和miR-361-3p的监管途径.

主要方法:

在体外:用Sev.治疗的微质细胞系.
在体内:暴露于Sev的小鼠,用莫里斯水迷宫进行评估.
分子分析:RT-qPCR,CCK-8,流细胞计,ELISA,双光酶记者测定,RNA免疫沉.

主要成果:

在体外和体内,Sev增加了BLACAT1的表达,并降低了miR-361-3p.
si-BLACAT1转染减轻了Sev诱导的细胞损伤,炎症和氧化应激.
BLACAT1针对miR-361-3p,而miR抑制剂逆转了保护作用.
在老鼠中,Sev 损害了学习和记忆.

结论:

BLACAT1通过miR-361-3p通路加剧了sevoflurane诱导的质细胞损伤.
这种机制有助于海马体的认知功能障碍在Sev暴露后.
针对BLACAT1/miR-361-3p可能为Sev相关的神经缺陷提供治疗策略.

关键词:

布莱卡特 (BLACAT) 是一个黑猫.miR‐361‐3p 的时间.微质细胞中的微质细胞神经毒性的作用.七伏氨酸是什么意思

更多相关视频

In Vitro Method to Control Concentrations of Halogenated Gases in Cultured Alveolar Epithelial Cells

In Vitro Method to Control Concentrations of Halogenated Gases in Cultured Alveolar Epithelial Cells

Published on: October 23, 2018

Assessing Changes in Synaptic Plasticity Using an Awake Closed-Head Injury Model of Mild Traumatic Brain Injury

Assessing Changes in Synaptic Plasticity Using an Awake Closed-Head Injury Model of Mild Traumatic Brain Injury

Published on: January 20, 2023

相关概念视频

Hepatic Encephalopathy

Hepatic Encephalopathy

DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic...